StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30102% above fair value
$168.98−1.28 (-0.75%)

Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%

Gilead Sciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Gilead Sciences's free cash flow for the twelve months ending Sep 30, 2026 was $13.78B, up 50.4% year over year. For fiscal 2025 it was $9.46B, down 8.2% from the year before. Over ten years it grew -7.4% a year on average. The highest annual figure on record is $20.50B in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.46B-8.2%
FY2024Dec 31, 2024$10.31B+38.9%
FY2023Dec 31, 2023$7.42B-11.1%
FY2022Dec 31, 2022$8.34B-22.8%
FY2021Dec 31, 2021$10.81B+43.7%
FY2020Dec 31, 2020$7.52B-9.6%
FY2019Dec 31, 2019$8.32B+11.3%
FY2018Dec 31, 2018$7.48B-33.9%
FY2017Dec 31, 2017$11.31B-30.6%
FY2016Dec 31, 2016$16.30B-20.5%
FY2015Dec 31, 2015$20.50B+67.2%
FY2014Dec 31, 2014$12.26B+320.6%
FY2013Dec 31, 2013$2.92B+4.2%
FY2012Dec 31, 2012$2.80B-20.2%
FY2011Dec 31, 2011$3.51B+26.5%
FY2010Dec 31, 2010$2.77B-2.7%
FY2009Dec 31, 2009$2.85B+40.5%
FY2008Dec 31, 2008$2.03B+27.5%
FY2007Dec 31, 2007$1.59B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.80B+21.1%
Q2 FY2026Jun 30, 2026$3.43B+376.8%
Q1 FY2026Mar 31, 2026$2.43B+46.8%
Q4 FY2025Dec 31, 2025$3.12B+10.4%
Q3 FY2025Sep 30, 2025$3.96B-5.0%
Q2 FY2025Jun 30, 2025$720.00M-39.7%
Q1 FY2025Mar 31, 2025$1.65B-21.8%
Q4 FY2024Dec 31, 2024$2.83B+44.7%
Q3 FY2024Sep 30, 2024$4.17B+155.2%
Q2 FY2024Jun 30, 2024$1.20B-45.7%
Q1 FY2024Mar 31, 2024$2.11B+29.3%
Q4 FY2023Dec 31, 2023$1.95B-18.1%
Q3 FY2023Sep 30, 2023$1.63B-39.7%
Q2 FY2023Jun 30, 2023$2.20B+32.5%
Q1 FY2023Mar 31, 2023$1.64B+2.6%
Q4 FY2022Dec 31, 2022$2.39B-21.7%
Q3 FY2022Sep 30, 2022$2.71B-13.1%
Q2 FY2022Jun 30, 2022$1.66B-24.5%
Q1 FY2022Mar 31, 2022$1.59B-34.8%
Q4 FY2021Dec 31, 2021$3.05B+75.7%
Q3 FY2021Sep 30, 2021$3.11B+48.6%
Q2 FY2021Jun 30, 2021$2.20B-9.3%
Q1 FY2021Mar 31, 2021$2.45B+93.3%
Q4 FY2020Dec 31, 2020$1.74B-27.0%
Q3 FY2020Sep 30, 2020$2.10B-14.3%
Q2 FY2020Jun 30, 2020$2.42B+12.3%
Q1 FY2020Mar 31, 2020$1.27B-5.6%
Q4 FY2019Dec 31, 2019$2.38B+13.4%
Q3 FY2019Sep 30, 2019$2.45B+19.6%
Q2 FY2019Jun 30, 2019$2.16B+69.0%
Q1 FY2019Mar 31, 2019$1.34B-34.9%
Q4 FY2018Dec 31, 2018$2.10B-17.2%
Q3 FY2018Sep 30, 2018$2.05B-20.3%
Q2 FY2018Jun 30, 2018$1.28B-62.5%
Q1 FY2018Mar 31, 2018$2.06B-26.7%
Q4 FY2017Dec 31, 2017$2.53B-24.8%
Q3 FY2017Sep 30, 2017$2.57B–
Q2 FY2017Jun 30, 2017$3.40B–
Q1 FY2017Mar 31, 2017$2.81B–
Q4 FY2016Dec 31, 2016$3.37B–

More Gilead Sciences figures

See a number that looks wrong?